The UAE is preparing to permit advertising of prescription-only medicines under regulated conditions, while requiring official clearance for all medical product promotions and maintaining a prohibition on endorsements by social media influencers.
The Emirates Drug Establishment (EDE) outlined the approach at a Medical Product Advertising Customer Council held at the Government Accelerators Centre in Emirates Towers, Dubai, on November 18. The discussions centred on introducing advertising for prescription-only medicines subject to approved regulatory controls, alongside stricter scrutiny of promotional claims and distribution channels.
The authority did not announce a date for implementing any additional permission for prescription-only medicine advertising or specify which products might qualify. Its announcement described regulatory updates discussed with industry participants rather than an unrestricted authorisation to promote medicines directly to consumers.
EDE stressed that pharmaceutical companies, healthcare providers and other eligible advertisers must secure approval before publishing or circulating promotional material. The requirement covers print publications, audio and video advertisements, outdoor display screens, websites and social media, with different documentation requirements depending on the medium and product involved.
Advertisements must provide accurate, clear information that accords with the product’s approved indications. Claims must be supported by evidence, misleading statements are prohibited, and relevant risks or side effects must be disclosed. Advertisers must also include appropriate warnings and disclaimers reflecting the product category and intended audience.
The regulator said promotional materials should not encourage members of the public to diagnose themselves or obtain prescription treatment without appropriate supervision from a healthcare professional. The distinction between advertising directed at doctors and other health professionals and material intended for the general public remains central to the applicable controls.
Social media influencers cannot advertise, promote or endorse medical products, EDE reiterated. The restriction applies even as licensed advertisers can seek permission to distribute approved promotional content through social media platforms. Approval to use a digital channel therefore does not remove restrictions on who can deliver the promotional message.
The council also examined how authorities inspect advertisements across media channels, identify breaches and coordinate the removal of material that fails to comply with the rules. The establishment said it would work with relevant authorities when action against non-compliant content was required.
The existing legal framework is set out in Federal Decree-Law No. 38 of 2024, which requires EDE approval for advertising medical products through visual, written, audio or social media channels. It permits the regulator to restrict promotion of particular products to designated audiences or prohibit it entirely where applicable.
Under the law, applicants must be licensed pharmaceutical or healthcare establishments. Ordinarily, the product must possess valid marketing authorisation from EDE, although specified exemptions apply. Each advertised product requires its own approval, valid for a period ranging from 30 days to one year, depending on the applicant’s request.
The legislation also prohibits public promotion of controlled or semi-controlled products and hazardous or toxic substances, including relevant chemical precursors. The restrictions cover products intended for veterinary as well as human use, underscoring that permission to advertise certain medicines does not extend to every regulated product.
EDE can cancel advertising approval if an applicant submits false information, publishes material that differs from the authorised version or no longer satisfies licensing requirements. Approval can also be withdrawn where subsequent clinical or safety information establishes that the advertised medicine is unsafe.
The regulator’s online licensing service lists an application fee of Dh100, with additional licence charges determined by the type of establishment and advertising format. It gives a standard service completion period of three working days, subject to applicants supplying the required documents.
Applicants use UAE PASS to access the service, complete the form and submit supporting evidence and the proposed advertisement. The material may include a printed design, video storyboard or audio script. Once approved, the advertiser must display the licence number and expiry date in accordance with the authorisation.
Council participants also discussed submission difficulties and opportunities to clarify the application process. EDE invited questions and feedback from pharmaceutical businesses, healthcare operators and other stakeholders about documentation, review procedures and the practical requirements of obtaining advertising licences. The meeting also addressed ways to improve customer guidance and reduce uncertainty over the information required for different advertising formats and product classifications during the application process.
Related Posts
Add A Comment
